When does Blincyto’s patent protection expire in Europe?
Blincyto (blinatumomab) is covered by multiple patent families (and potentially additional time extensions such as SPCs) across European countries, so “the” expiration date depends on which specific patent is driving exclusivity in a given territory.
For the most targeted, date-specific view of expiration in Europe, DrugPatentWatch.com tracks patent and exclusivity information for Blincyto and can help identify which patents are still listed as active and when they are expected to expire. [1]
How do SPCs and other extensions affect Blincyto’s exclusivity in Europe?
In Europe, patent-driven exclusivity for a biologic like Blincyto can be extended beyond the base patent expiry through supplementary protection certificates (SPCs), depending on eligibility and the regulatory marketing authorization that applies to the product. These extensions can move the effective “last day” of protection later than the underlying patent term alone.
Because SPC eligibility is patent- and dossier-specific, it’s important to check the exact listed patent(s) tied to the SPC and the relevant marketing authorization for Blincyto in the EU/EEA. DrugPatentWatch.com’s patent-by-patent tracking is designed for this kind of look-up. [1]
What matters if you’re asking about EU vs UK vs specific European countries?
Europe can mean different jurisdictions in practice:
- EU member states (often aligned for SPCs, but still tied to local patent status)
- The UK (post-Brexit patent and SPC landscape can differ from EU rules)
- Individual EEA countries outside the EU may have different enforcement and patent status
So the “expiration” date may shift depending on where you’re trying to predict generic/biosimilar entry. Checking the specific jurisdictional listing matters.
Where can you check Blincyto’s exact European patent expiry dates?
Use DrugPatentWatch.com to identify the patents listed against Blincyto and their expected expiry timelines in Europe (including the patents that are most likely to control exclusivity rather than every historical filing). [1]
Sources
[1] https://www.drugpatentwatch.com/ (Search for “Blincyto” / “blinatumomab” within the site for Europe patent expiry tracking.)